Superluminal Medicines, a biotechnology company focused on integrating artificial intelligence, machine learning, protein dynamics and structural biology, has closed an oversubscribed $60 million Series B financing. The round was led by BVF Partners, with participation from Deep Track Capital, Perceptive Advisors and existing investors including RA Capital Management, Insight Partners, NVIDIA, Eli Lilly and Company, Cooley and Gaingels. The new capital will support clinical development and expansion of the company’s GPCR-focused discovery platform.
Advancing a Rare Obesity Program
Superluminal’s lead clinical program is a selective, biased MC4R agonist being developed for rare genetic forms of obesity and hypothalamic obesity, two areas with limited treatment options. A Phase 1 clinical trial is expected to begin by the end of 2026. The company believes the candidate’s design may maximize therapeutic activity while minimizing side effects by activating only the signaling pathways responsible for the desired clinical effect.
Targeting the MC4R Pathway
The MC4R pathway is a clinically validated regulator of energy homeostasis and appetite, with established relevance in rare genetic forms of obesity, including Bardet-Biedl syndrome and hypothalamic obesity. Because MC4R signaling also plays a role in many metabolic conditions, the program may have future applications in rare diseases such as Prader-Willi syndrome and in broader populations in combination with GLP-1 therapies. Preclinical studies demonstrated high selectivity and a favorable safety profile for the candidate across relevant models.
Platform and Collaborations
Superluminal has pioneered the integration of advanced structural biology with proprietary machine learning tools to accelerate the discovery of candidate-ready small molecules across challenging target classes. Its platform combines Agentic Cryo-EM capabilities, GPCR-focused co-folding models, de novo small-molecule design, predictive ADME and toxicology models, and novel GPCR biophysics. Beyond its wholly owned pipeline, the company continues to advance strategic collaborations, including a partnership with Eli Lilly and Company targeting undisclosed GPCRs for cardiometabolic diseases and obesity.
Pipeline Expansion
Beyond the lead MC4R program, the Series B proceeds will support advancement of additional pipeline programs and further expansion of next-generation small-molecule GPCR-targeted therapies for endocrine and cardiometabolic diseases. Superluminal’s approach is designed to explore functional selectivity and structural complexity at an unprecedented scale across diverse receptor conformations. The company expects these capabilities to support a sustainable pipeline in areas of high unmet need.
Investor Confidence
Investors emphasized the significance of the company’s transition from a discovery platform company to a clinical-stage biotechnology company. BVF Partners stated that the lead MC4R program has the potential to address a serious unmet need for patients with rare genetic forms of obesity and related conditions. RA Capital Management noted that the caliber of the financing syndicate reflects growing confidence in Superluminal’s platform, technology and team.
With an oversubscribed financing round and a clear clinical milestone ahead, Superluminal Medicines is positioned to advance its lead MC4R agonist into human testing by the end of 2026. The company’s integrated discovery engine and strategic investor base provide support for a broader pipeline of small-molecule GPCR-targeted therapies in endocrine and cardiometabolic diseases. The announcement marks an important step in translating structural biology and machine learning into potential new treatment options for patients with significant unmet medical needs.